Kader Thiam

Company: genOway

Job title: Vice President of Transgenic Technologies

Seminars:

Immune Checkpoints; Humanised Preclinical Models for Biologics’ Efficacy & MoA 2:45 pm

Exploring how model design impacts the physiological relevance and the predictability of preclinical outcomesRead more

day: Day One

Panel Discussion: Limitations of Humanised & PDX Models 2:00 pm

How can we push these borders to include more supporting immune cells, dendritic cells, NK-cells? Increasing longevity; CD34 humanised hyper immune-deficient mice can increase available study lengths but also increase the cost. Is there a middle ground? Gaining data on persistence of cellular therapies without requiring additional miceRead more

day: Day One